home / stock / roivw / roivw quote
Last: | $2.75 |
---|---|
Change Percent: | 0.0% |
Open: | $2.86 |
Close: | $2.75 |
High: | $2.9199 |
Low: | $2.75 |
Volume: | 37,827 |
Last Trade Date Time: | 09/01/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.75 | $2.86 | $2.75 | $2.9199 | $2.75 | 37,827 | 09-04-2023 |
$2.75 | $2.86 | $2.75 | $2.9199 | $2.75 | 37,827 | 09-01-2023 |
$2.86 | $2.85 | $2.86 | $2.93 | $2.84 | 43,748 | 08-31-2023 |
$2.87 | $2.79 | $2.87 | $2.91 | $2.79 | 30,330 | 08-30-2023 |
$2.79 | $2.78 | $2.79 | $2.85 | $2.78 | 64,172 | 08-29-2023 |
$2.79 | $2.91 | $2.79 | $2.91 | $2.76 | 245,035 | 08-28-2023 |
$2.72 | $2.84 | $2.72 | $2.84 | $2.72 | 171,870 | 08-25-2023 |
$2.75 | $2.84 | $2.75 | $2.91 | $2.75 | 61,828 | 08-24-2023 |
$2.84 | $2.99 | $2.84 | $2.99 | $2.84 | 233,874 | 08-23-2023 |
$2.76 | $2.71 | $2.76 | $2.79 | $2.69 | 114,572 | 08-22-2023 |
$2.72 | $2.64 | $2.72 | $2.72 | $2.605 | 101,693 | 08-21-2023 |
$2.7 | $2.61 | $2.7 | $2.73 | $2.61 | 21,936 | 08-18-2023 |
$2.61 | $2.71 | $2.61 | $2.9716 | $2.57 | 23,251 | 08-17-2023 |
$2.68 | $2.69 | $2.68 | $2.69 | $2.6 | 80,186 | 08-16-2023 |
$2.74 | $2.79 | $2.74 | $2.91 | $2.69 | 19,873 | 08-15-2023 |
$2.89 | $2.68 | $2.89 | $3.03 | $2.68 | 162,644 | 08-14-2023 |
$2.94 | $2.8 | $2.94 | $2.9443 | $2.8 | 30,413 | 08-11-2023 |
$2.8472 | $2.92 | $2.8472 | $2.92 | $2.77 | 786,765 | 08-10-2023 |
$2.8 | $2.93 | $2.8 | $2.94 | $2.77 | 1,741,341 | 08-09-2023 |
$2.86 | $2.86 | $2.86 | $2.96 | $2.86 | 34,757 | 08-08-2023 |
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Warrant Company Name:
ROIVW Stock Symbol:
NASDAQ Market:
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 million Sumitomo Pharma repurchase reduces shares outstanding by 9% In the ...
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the...
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update. Roivant completed the sale of Telavant to Roche for $7.1B with an additi...